A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; Ibrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 11 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2019 to 1 Dec 2019.
- 08 Oct 2019 Status changed from not yet recruiting to recruiting.
- 29 Aug 2019 Planned End Date changed from 1 Jul 2024 to 1 Oct 2024.